Skip to main content
OpenTrials
Completed

NCT Number: NCT03910868

Impact of P-gp, MRP2, ENT-1 and CNT3 on the Blood Concentration / Intra-PBMC Concentration of Tacrolimus

Prospective and monocentric pharmacokinetic study

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Rennes University Hospital

Rennes, 35033, France

About this study

Membrane transporters supporting tacrolimus at the lymphocyte level may play a role in the variability of the relationship between tacrolimus blood concentration and intracellular concentration, or may be the main explanatory factors. Nevertheless, most of the studies carried out on the subject, have been by genetic approach, neglecting in fact the membrane expression of these transporters, which could testify more to the real effect on the transport of tacrolimus. A better understanding of the cellular transport mechanisms of tacrolimus in the T lymphocyte could thus make it possible to identify sub-populations of patients under-exposed at the intra-lymphocyte level, despite satisfactory systemic exposure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult of 18 or over;
  • fully and honestly informed, and not having reported his non-opposition to the use of his samples for research;
  • Affiliated to a social security scheme;
  • Hepatic and / or renal transplant stable between two and twenty-four months after transplantation, treated with tacrolimus;
  • Without modification of immunosuppressive treatment or treatment likely to modify their pharmacokinetics (imidazoles, macrolides ...) during the last two weeks;
  • Each patient can only be included once.

Exclusion criteria

  • Participation in another protocol whose procedures are incompatible with the realization of the study;
  • Pregnant woman ;
  • Major person subject to legal protection (safeguard of justice, guardianship, tutorship);
  • Person deprived of liberty;
  • Opposition to the use of clinical data and remnants of samples taken from care for research purposes.

Treatment and study plan

Primary outcomes

  1. Correlation between drug transporters expression (RNA and protein) in PBMC and tacrolimus intra-PBMC concentration

    Time frame: During the consultation (between 2 and 24 months after the transplant)

    The mRNA levels will be recorded as a cycle threshold difference between the studied gene, and the mean of two housekeeping genes (ACTB and B2M). The proteic expression of the studied transporters will be recorded as fluorescent intensity levels

Secondary outcomes

  1. Correlation between drug transporters RNA expression in PBMC and drug transporters protein expression in PBMC

    Time frame: During the consultation (between 2 and 24 months after the transplant)

    The mRNA levels will be recorded as a cycle threshold difference between the studied gene, and the mean of two housekeeping genes (ACTB and B2M). The proteic expression of the studied transporters will be recorded as fluorescent intensity levels

  2. Correlation between tacrolimus blood to intracellular ratio and adverse events.

    Time frame: During the consultation (between 2 and 24 months after the transplant)

    Tacrolimus-related adverse effects as recorded on the medical record of the patient.

  3. Correlation between tacrolimus intra-PBMC concentration and treatment outcome

    Time frame: During the consultation (between 2 and 24 months after the transplant)

    Treatment outcome as recorded on the medical record of the patient.

  4. Correlation between tacrolimus intra-PBMC concentration and comedications

    Time frame: During the consultation (between 2 and 24 months after the transplant)

    Co-medications as recorded on the medical record of the patient.

  5. Correlation between tacrolimus intra-PBMC concentrations and Donor Graft cell-free DNA (cf-DNA) concentration

    Time frame: During the consultation (between 2 and 24 months after the transplant)

    Donor graft cf-DNA characterized the cell death marker, released from necrotic or apoptotic cells in the transplant organ, and may therefore be useful as a marker for graft injury. When its plasma concentration increases, it evidences that a lesion process occurs in the graft

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Official study title

Study of the Impact of P-gp, MRP2, ENT-1 and CNT3 on the Blood Concentration / Intra-PBMC Concentration of Tacrolimus in Liver and Kidney Transplant Patients

Acronym: TRANS-TAC

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 10, 2019
Registry last updated
Jan 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.